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Abstract
Background: The gefitinib compassionate-use programme has enabled >39,000 patients
worldwide to receive gefitinib ('Iressa', ZD1839) treatment. This paper reports the outcome of
gefitinib treatment in Chinese patients who enrolled into the 'Iressa' Expanded Access Programme
(EAP) at the Peking Union Medical College Hospital.
Methods: Thirty-one patients with advanced or metastatic non-small-cell lung cancer (NSCLC)
that had progressed after prior systemic chemotherapy were eligible to receive oral gefitinib 250
mg/day as part of the EAP. Treatment was continued until disease progression or unacceptable
toxicity occurred. The impact of treatment on disease-related symptoms and quality of life (QoL)
was evaluated with the Chinese versions of European Organization for Research and Treatment of
Cancer Quality of Life Questionnaires (EORTC QLQ-C30 and QLQ-LC13).
Results: Gefitinib was well tolerated. Adverse events (AEs) were generally mild (grade1 and 2) and
reversible. The most frequent AEs were acneform rash and diarrhoea. Only one patient withdrew
from the study due to a drug-related AE. The objective tumour response rate was 35.5% (95%
confidence interval [CI]: 18.6–52.3); median progression-free survival was 5.5 months (95% CI, 1.6
to 9.4); median overall survival was 11.5 months (95% CI, 5.6 to 17.3). The QoL response rates for
five functioning scales and global QoL varied from 56–88%. The main symptom response rates
varied from 44–84%. QoL and symptom response were correlated with objective tumour
response.
Conclusion: Gefitinib demonstrated safety and efficacy as monotherapy in this series of Chinese
patients with advanced NSCLC and was also associated with remarkable symptom relief and
improvement in QoL. Although clinical trials are needed to confirm these positive findings, the data
suggest that treatment with gefitinib may be beneficial for some Chinese patients who do not
respond to chemotherapy and have poor prognosis.
Published: 19 August 2004
BMC Cancer 2004, 4:51 doi:10.1186/1471-2407-4-51
Received: 22 May 2004
Accepted: 19 August 2004
This article is available from: http://www.biomedcentral.com/1471-2407/4/51
© 2004 Mu et al; licensee BioMed Central Ltd. 
This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 8
(page number not for citation purposes)
BMC Cancer 2004, 4:51 http://www.biomedcentral.com/1471-2407/4/51Background
Platinum-based combination chemotherapy is the stand-
ard first-line treatment for patients with advanced non-
small-cell lung cancer (NSCLC). Although meta-analysis
of clinical trials proved that combination chemotherapy
for advanced NSCLC is superior to best supportive care [1]
and new cytotoxic agents have been developed over the
past decade, the 5-year survival rate for these patients
remains <1% [2]. The pace of progress is too slow and new
therapeutic approaches are required. Based on our
increasing understanding of the biology of NSCLC, tar-
geted therapy is providing some promising new agents.
Targeted therapy is usually aimed at a key protein impli-
cated in tumour cell proliferation, survival, invasion or
resistance to conventional treatments but spares the nor-
mal cells, thereby producing less toxicity than conven-
tional therapies [3].
Many solid tumours express or highly express the epider-
mal growth factor receptor (EGFR). In lung cancer, dereg-
ulation of EGFR is seen mainly in NSCLC: EGFR is highly
expressed in NSCLC at levels varying from 32–80% [4-6].
Abnormal signal transduction arising from the receptor is
implicated in the growth and proliferation of these
tumours. Thus, disruption of the EGFR signal transduc-
tion pathway is an ideal target for anticancer therapy.
Gefitinib is an orally active small molecule EGFR tyrosine
kinase inhibitor (EGFR-TKI). The tolerability and efficacy
of gefitinib have been explored extensively in the West
and Japan. In a Phase I trial, Nakagawa et al compared the
safety profile, pharmacokinetic parameters and antitu-
mour activity of gefitinib in patients with solid malignant
tumours in Japan, the USA and Europe, and no significant
difference was found for ethnicity [7]. However, severe
interstitial pneumonia related to gefitinib therapy was
more common in the Japanese population [8,9]. In IDEAL
('Iressa' Dose Evaluation in Advanced Lung cancer) 1,
which included 102 Japanese patients with advanced
NSCLC, the response rate of Japanese patients taking gefit-
inib was significantly higher than that of non-Japanese
patients but bias of baseline factors between strata, not
ethnicity, was thought to account for the difference [10].
But Owing to the paucity of current data on gefitinib
between defferent races, the possibility of differences in
the toxicity and efficacy of gefitinib for ethnicity cannot be
excluded. At present, there are few data regarding the tol-
erability and efficacy of gefitinib in Chinese patients.
Patients with advanced NSCLC who had no alternative
therapeutic options have been able to receive gefitinib
treatment in a worldwide compassionate-use programme.
Here we report the outcome of treatment with oral gefit-
inib 250 mg/day in Chinese patients with advanced
NSCLC participating in the compassionate-use pro-
gramme at Peking Union Medical College Hospital.
Methods
Patient population
Patients aged ≥18 years with histologically or cytologically
confirmed advanced or metastatic NSCLC were eligible
for enrolment into the compassionate-use programme
after providing written, informed consent. They were
required to have failed prior chemotherapy, and had no
other treatment options available. Patients who had
received chemotherapy were included if the treatment
ended >28 days prior to the study. Other eligibility criteria
included: adequate bone marrow function (white blood
cell count >4 × 109/L, absolute neutrophil count >1.5 ×
109 cells/L, platelet count >100 × 109/L); liver function
(total bilirubin <34 µmol/L, aspartate aminotransferase
[AST] <40 IU/L, alkanine aminotransferase [ALT] <41 IU/
L); renal function (serum creatinine <150 µmol/L, blood
urea nitrogen <10.7 mmol/L); PaO2 >60 mmHg.
Exclusion criteria included a serious pre-existing medical
condition (eg uncontrolled infection, interstitial pneumo-
nia or pulmonary fibrosis, severe chronic diarrhoea),
pregnancy and lactation.
Drug administration
One oral gefitinib tablet (250 mg) was taken at about the
same time each day. Gefitinib was administered every day
without interruption unless disease progression or unac-
ceptable toxicity occurred.
Evaluation before and during treatment
In this study, 28 days of treatment was defined as one
treatment cycle. Baseline evaluation included medical his-
tory and physical examination, electrocardiogram, chest
X-ray, thorax computed-tomography scan and ultrasonog-
raphy of the upper abdomen. Laboratory investigations
included complete blood counts, urinalysis, and renal
and liver function tests. Performance status (PS) was eval-
uated according to Eastern Cooperative Oncology Group
(ECOG) criteria. Brain magnetic resonance imaging and
radionuclide bone scans were only performed if meta-
static disease was suspected according to the clinical man-
ifestations of each patient. Regarding interstitial lung
disease, we paid attention to clinical respiratory symp-
toms (e.g. dyspnea, cough) and radiographic findings of
patients, and monitored PaO2 during therapy. Patients
were evaluated after the first and third cycles of therapy,
then every three cycles. Tumour response was evaluated
according to Response Evaluation Criteria In Solid
Tumors [11]. In line with the criteria, all patients included
in the study were assessed for response to treatment. Each
patient was assigned to one of the following categories:
complete response (CR); partial response (PR); stablePage 2 of 8
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lung cancer; early death from toxicity; early death because
of other disease; unknown (not assessable or insufficient
data). All AEs were recorded and graded according to
National Cancer Institute Common Toxicity Criteria ver-
sion 2.0.
Assessment of QoL
QoL was assessed using the Chinese version of the Euro-
pean Organization for Research and Treatment of Cancer
(EORTC) core questionnaire, the Quality of Life Ques-
tionnaire (QLQ)-C30 (version 3.0) and the supplemental
lung-cancer-specific module QLQ-LC13 [12]. Following
the scoring procedure recommended by the EORTC,
scores were converted into linear transformation ranging
from 0–100. For the functional and global health status/
QoL, higher scales represent better functioning. For symp-
toms, a higher score represents worse symptoms [13].
QoL and disease-related symptoms were assessed before
the start of the therapy and then at the end of each cycle
in the first 3 months of treatment.
Statistical analysis
Logistical regression test models were used to identify
baseline factors (gender, PS, histology, TNM stage and
prior chemotherapy) that might independently predict
tumour response. Median progression-free survival (PFS)
and overall survival (OS) were calculated using the Kap-
lan-Meier method and a log-rank test was used to detect
differences OS between strata.
Changes in symptoms and QoL were assessed in two dif-
ferent ways. Firstly, the mean scores of QoL and disease-
related symptoms at baseline were compared with those
at the end of the second cycle of treatment using a paired-
sample t test. Secondly, the response rates of symptoms
and QoL were calculated. For the assessment of symptoms
and QoL, the classification system suggested by Stephens
et al was used [14]. The results were presented as response
(ie improvement, control or prevention), no response and
nonevaluable cases in the form of percentages. The classi-
fication system [15,16] has been used successfully to eval-
uate QoL and symptoms in patients with lung cancer.
Response rates for QoL and disease-related symptoms
were compared between patients with and without objec-




Thirty-one eligible patients were enrolled into the EAP at
Peking Union Medical College Hospital between October
2002 and October 2003. Patient characteristics are listed
in Table 1. The patient series included 18 (58%) men and
13 (42%) women between 28 and 85 years of age
(median age 64). All patients had received at least one
platinum-based regimen and most had received more
than two regimens (different combinations including
platinum, taxane, docetaxel and gemcitabine). Ten
(32.3%) patients had squamous-cell carcinoma (SCC)
and 20 (64.5%) had adenocarcinoma. Most patients
(61.3%) had an ECOG PS of 0–1, 25.8% had a PS of 2 and
12.9% had a PS of 3. TNM stages were as follows: stage
IIIa, 1 patient; stage IIIb, 4 patients; stage IV, 26 patients.
Toxicity
All patients were assessed for toxicity. Twenty-three (74%)
patients had at least one AE. Treatment-related toxicities
are listed in Table 2. Almost all AEs (but for one grade 3
acneform rash) were mild (grade 1 or 2). The most fre-
quently reported AEs during treatment were acneform
rash (67.7%) and diarrhoea (35.5%). Four (12.9%)
patients had grade 1 or 2 stomatitis. Other AEs included
nausea (6.5%), vomiting (3.2%), increased ALT (3.2%)
and increased AST (3.2%). The majority of AEs were tran-
sient and reversible. Only one patient withdrew from
treatment due to an AE (on the 50th day of treatment with
grade 3 skin rash and exacerbation of dysphagia). This
patient had SCC, a PS of 3 and mediastinal lymph node
metastases before treatment. The patient suffered moder-
ate haemoptysis prior to gefitinib therapy, which reduced
to a mild severity during therapy. Fifteen days after with-
drawal from treatment, the patient died of massive
haemoptysis.
Table 1: Characteristics of patient series (n = 31)

















Prior chemotherapy, n (%)
1 regimen 5 (16.1)
2 regimens 10 (32.3)
≥3 regimens 16 (51.6)
ECOG, Eastern Cooperative Oncology Group; PS, performance 
statusPage 3 of 8
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The assessment of patient response is listed in Table 3. Of
the 31 patients, 1 (3.2%) achieved CR and 10 (32.3%)
achieved PR with an overall objective response rate of
35.5% (95% confidence interval [CI]: 18.6–52.3). SD was
documented in 7 (22.6%) patients and the overall DCR
(CR+PR+SD) was 58.1% (95% CI: 49.2–67.0). The
response rate of adenocarcinoma was significantly higher
than that of squamose carcinoma [50% (10/20) vs. 10%
(1/10)]. Multivariate logistic analysis also showed that the
odds of objective response were 10 times higher (odds
ratio 10; 95% CI: 1.0 to 93.4; p = 0.028) for patients with
adenocarcinoma than for patients with other tumour his-
tologies. Of the 31 patients who received treatment, 2
Patient response for QoL and main symptoms QoL, quality of life; PF, physical functioning; RF, role functioning; EF, emotional functioning; CF, cognitive fu ctioning; SF, social functioningFigure 1
Patient response for QoL and main symptoms QoL, quality of life; PF, physical functioning; RF, role functioning; EF, emotional 
functioning; CF, cognitive functioning; SF, social functioning
Table 2: Treatment-related toxicity (n = 31)
Adverse events Grade Total
1 2 3
n % n % n % n %
Acneform rash 17 54.8 3 9.7 1 3.2 21 67.7
Diarrhoea 10 32.3 1 3.2 - - 11 35.5
Nausea 1 3.2 1 3.2 - - 2 6.5
Vomiting - - 1 3.2 - - 1 3.2
Stomatitis 4 12.9 - - - - 4 12.9
Increased ALT 1 3.2 - - - - 1 3.2
Increased AST 1 3.2 - - - - 1 3.2
ALT, alkaline aminotransferase; AST, aspartate aminotransferasePage 4 of 8
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patients had SCC and a PS of 3, and no improvement in
either patient had been observed during gefitinib
treatment.
Median PFS was 5.5 months (95% CI, 1.6 to 9.4); median
OS was 11.5 months (95% CI, 5.6 to 17.3). The tumor
response was associated with improved OS. Median OS of
patients with response was significantly higher than that
of those with no response (log-rank test p = 0.0058) (17
vs. 4.4 months).
QoL and symptom improvement
At baseline, 25 (81% [25/31]) patients returned QoL
questionnaires. All 25 patients returned the question-
naires at the first cycle of therapy, 23 (93% [23/25] of
those patients returning questionnaires and remaining
alive) at the second cycle of therapy, and 18 (74% [18/24]
of those patinets returning questionnaires and remaining
alive) at the third cycle. The most frequently reported gen-
eral symptoms were fatigue (100%) and appetite loss
(68%), while dyspnoea (100%) and coughing (84%)
were the most frequently reported respiratory symptoms.
The changes in the mean scores for symptom scales, func-
tioning and global QoL scales are presented in Table 4. A
statistically significant increase in mean score was
observed for physical functioning, role functioning, emo-
tional functioning, social functioning and global QoL
after 8 weeks of treatment. There was also a trend towards
a higher score (p = 0.08) for cognitive functioning. Mean
scores for two general symptoms (fatigue and appetite
loss) and disease-related symptoms (dyspnoea, coughing,
pain in chest, pain in arm or shoulder and pain in other
parts) decreased statistically.
Patient responses for functioning, global QoL and main
symptoms are shown in figure 1. A >50% response rate
was observed in all five functioning criteria and global
QoL. With regard to QoL, the highest response rate was
observed for emotional functioning (88%), followed by
cognitive (72%), physical (68%), social (64%) and role
functioning (60%), and global QoL (56%).
Haemoptysis had the highest response rate (84%), the
rate of improvement (63%) being just lower than that of
appetite loss among the five symptoms. The response
rates for dyspnoea and coughing were 56% and 68%,
respectively. For fatigue and appetite, the response rates
were 44% and 80%, respectively.
Differences in response rates for symptoms and QoL
between patients with or without objective tumour
response are shown in Table 5. Response rates of physical
functioning, role functioning, social functioning and glo-
bal QoL were significantly higher in patients with
objective tumour response than in those without.
Response rates for emotional functioning and cognitive
functioning were also higher in patients with tumour
response, though the difference was not statistically signif-
icant. Differences were also observed in response rates for
symptoms. For dyspnoea, coughing, appetite loss and
fatigue, the response rates in the objective responders
were higher than those in nonresponders. No significant
association was found between haemoptysis and objec-
tive tumour response.
Discussion
A daily oral 250 mg dose of gefitinib was well tolerated in
this series of Chinese patients with advanced NSCLC, who
received gefitinib as part of a compassionate-use pro-
gramme. AEs were mild and reversible and different to
those associated with conventional chemotherapy, such
as neutropenia, thrombocytopenia and neuropathy. No
haematological or neural toxicity was observed in the
study. As with prior clinical trials evaluating the toxicity of
gefitinib, the most frequently reported AEs were acneform
rash and diarrhoea (grade 1 or 2). Four patients developed
grade 1 or 2 stomatitis during treatment, which has previ-
ously been associated with gefitinib treatment in 7.8% of
patients in IDEAL 1 but was not reported in IDEAL 2 [17].
Severe acute interstitial pneumonia is the most serious AE
that has been linked with gefitinib therapy. Inoue et al
recently reported that 4 of 18 patients receiving gefitinib
in their clinic developed severe acute interstitial pneumo-
nia [8]. The authors stated that 291 of 17,500 patients
(1.7%) treated with gefitinib in Japan had developed sus-
pected interstitial pneumonia or acute lung injury. In
contrast to the higher incidence of interstitial pneumonia,
this severe AE was lower in the rest of the world [9]. The
worldwide frequency of interstitial lung disease to date in
~92,750 patients who have received gefitinib is <1.0%
[18]. The ethnicity between Chinese and Japanese people
is probably similar, but we saw no evidence of interstitial
pneumonia in the series of patients. Although no patients
Table 3: Tumour response (n = 31)
Patients
Complete response, n (%) 1 (3.2)
Partial response, n (%) 10 (32.3)
Stable disease, n (%) 7 (22.6)
Progressive disease, n (%) 11 (35.5)
Early death, n (%) 2 (6.5)
Response rate, % (95% CI) 35.5 (18.6–52.3)
Disease control rate, % (95% CI) 58.1 (49.2–67.0)
CI, confidence intervalPage 5 of 8
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drug-related interstitial lung disease could not be
excluded because of the small number of patients in our
series.
The response rate (35.5%) was higher than that of recently
presented Phase II trials (18.4% and 11.8% in patients
receiving gefitinib 250 mg/day in IDEAL 1 and 2, respec-
tively). The DCRs were 54.4% and 42% for the 250 mg/
day dose in IDEAL 1 and 2, respectively, in contrast to
58.1% in our study. Unlike IDEAL 2, which was
performed in the USA, IDEAL 1 was a global trial that
recruited patients from 43 centres across Europe, Aus-
tralia, South Africa and Japan and included a total of 102
Japanese patients with advanced NSCLC. The response
rate for Japanese patients was higher than that of non-Jap-
anese patients (27.5% versus 10.45%; odds ratio 3.72; p =
0.0023). However, the difference in response rate for eth-
nicity was not verified using multivariate logistical regres-
sion analysis. The difference in response rate between
Japanese and non-Japanese patients was attributed to bias
Table 4: Changes in mean score for QoL and symptoms
QoL items Baseline mean (standard deviation) 2nd cycle mean (standard deviation) p value
Global QoL 36.0 (24.7) 55.4 (16.2) 0.01
Physical functioning 47.47 (24.74) 65.22 (20.59) 0.01
Role functioning 42.67 (35.05) 56.52 (25.99) 0.03
Emotional functioning 67.67 (28.39) 84.78 (19.57) <0.01
Cognitive functioning 66.00 (28.66) 76.09 (18.69) 0.08
Social functioning 42.67 (32.30) 60.87 (26.88) 0.01
Symptoms items
Fatigue 64.89 (25.99) 45.89 (22.30) <0.01
Appetite loss 41.33 (36.36) 20.29 (24.08) 0.01
Dyspnoea 60.44 (28.16) 39.61 (23.88) <0.01
Coughing 58.67 (36.36) 28.99 (30.66) <0.01
Haemoptysis 12.00 (18.95) 7.25 (17.28) 0.21
Pain in chest 36.00 (33.22) 17.39 (19.77) 0.04
Pain in arm or shoulder 24.00 (28.09) 13.04 (19.43) 0.03
Pain in other parts 25.33 (27.69) 14.49 (22.08) 0.02
QoL, quality of life
Table 5: QoL and symptom response rates among objective tumour responders and nonresponders
Items Responders (n = 11) Nonresponders (n = 14) p value
n % n %
QoL
Global QoL 10 91 4 29 0.004
PF 10 91 7 50 0.042
RF 10 91 5 36 0.012
EF 11 100 11 79 0.23
CF 10 91 8 57 0.09
SF 10 91 6 43 0.033
Symptoms
dyspnoea 9 82 5 36 0.021
coughing 10 91 7 50 0.042
haemoptysis 11 100 10 71 0.105
appetite loss 11 100 9 64 0.046
fatigue 8 73 3 21 0.01
QoL, quality of life; PF, physical functioning; RF, role functioning; EF, emotional functioning; CF, cognitive functioning; SF, social functioningPage 6 of 8
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histology) [19,10].
QoL is an important endpoint for assessment of gefitinib
treatment and has been included in some phase I and
phase II trials. In these trials, the Functional Assessment of
Cancer Therapy – Lung questionnaire was used to assess
QoL and symptoms. Its validation and sensitivity were
verified. Significant improvements in symptoms and QoL
were observed in IDEAL 1 and 2. In IDEAL 1, symptom
and QoL improvement with a dose of 250 mg/day were
40.3% and 23.9%, respectively, and in IDEAL 2 they were
43.1% and 34.3%, respectively. In both trials, improve-
ments in symptoms and QoL correlated well with tumour
response [20].
In our patient series, the EORTC QLQ-C30 and its supple-
ment module QLQ-LC13 were used for assessment of
QoL and symptoms. Together, they are thought to be one
of the best developed instruments for lung cancer assess-
ment [21]. The questionnaires have been translated into
>20 languages and validation of the standard Chinese ver-
sion has been verified [22]. In our series of patients, mean
scores of four functioning scales (physical, role, emo-
tional and social functioning) and global QoL increased
significantly after 8 weeks of treatment and were associ-
ated with high response from 56–88%. Mean score of cog-
nitive functioning also increased, from 66 at baseline to
76 at the end of second cycle with response of 72% (not
statistically significant; p = 0.08). General and disease-
related symptom scores increased from 44% to 84%.
Importantly, improvement of symptoms and QoL
correlated with objective tumour response. Patients with
objective tumour response had higher rates of symptom
and QoL response. The results indicate that placebo effect
is unlikely to explain completely the improvement in
symptoms and QoL with gefitinib, though there is no pla-
cebo control in our patient series or the EAP. Emotional
functioning response was observed in all patients with
objective tumour response, but this was not statistically
significant when compared with nonresponders (100%
versus 79%; p = 0.23). As emotional functioning con-
tained more subjective questions, such as "Did you feel
tense?", "Did you worry?", "Did you feel irritable?" and
"Did you feel depressed?", the limited difference of emo-
tional functioning response between responders and non-
responders with gefitinib cannot completely exclude the
possibility of placebo effect. Thus, a placebo control
group should be included in future studies of QoL and
symptom improvement with gefitinib.
Conclusions
In conclusion, the data from this patient series show that
an oral dose of gefitinib 250 mg/day is well tolerated and
has significant antitumour activity in Chinese patients
with advanced NSCLC who had failed previous chemo-
therapy and for whom no other treatment options were
available. Although clinical trials are needed to confirm
these positive findings, the data suggest that treatment
with gefitinib may be beneficial for some Chinese patients
who do not respond to chemotherapy and have poor
prognosis.
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